$83.92▾ 0.10%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-422.51MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+2336.3%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Crinetics Pharmaceuticals, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is growing strongly year over year.
Key numbers
Valuation
EPS (TTM)$-5.04
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-1189.9%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$42.16M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days8 articles
5 bullish1 neutral2 bearish
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover TargetHalper Sadeh LLC is Investigating Whether ESI, CRNX, SOLS are Obtaining Fair Deals for their Shareholders
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Why This Pharmaceutical Stock Jumped Close to 100% This Week
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.